Sponsor or institution

Clinical trials and research at Boehringer Ingelheim

• 48Clinical trials
• 64Countries

Newest trials

All recruiting trials (48)

• Testing different doses of BI 3968621 alone or with ezabenlimab in adults with advanced cancer

  This study tests whether BI 3968621, alone or with ezabenlimab, can be given safely at different doses to adults with advanced solid tumors and whether it can slow or shrink tumors.

  Recruiting at 3 sites Phase 1 Boehringer Ingelheim · Sarasota, Florida and 9 other locations · NCT07851103

• Bioequivalence test of two Vicadrostat/Empagliflozin formulations in healthy adults

  This study tests whether two different oral formulations of Vicadrostat with Empagliflozin behave the same in the body of healthy adults.

  Recruiting Phase 1 Boehringer Ingelheim · Biberach · NCT07845630

• Obrixtamig and Pumitamig in Advanced Small Cell Lung Cancer (Dareon-Rosetta35)

  This trial tests whether obrixtamig with pumitamig, alone or with standard chemotherapy, can help people with extensive-stage small cell lung cancer tolerate treatment and shrink tumors.

  Recruiting at 2 sites Phase 1/2 Boehringer Ingelheim · Miami, Florida and 26 other locations · NCT07843940

• How BI 3034701 gets into the blood when given in two different forms in healthy adults

  This early two-way comparison tests whether two formulations of BI 3034701 deliver different amounts into the bloodstream in healthy adults.

  Recruiting Phase 1 Boehringer Ingelheim · Nottingham · NCT07837648

• Zongertinib tablets from two makers: do they behave the same when taken with or without food

  This early study tests whether two different Zongertinib tablet formulations give similar body levels in healthy adults when taken by mouth, with or without food.

  Recruiting Phase 1 Boehringer Ingelheim · Biberach · NCT07789028

• Carbamazepine and Verducatib: How the Drug Interaction Might Change Blood Levels in Healthy Men

  This study tests whether carbamazepine changes the amount of verducatib in the blood of healthy men.

  Recruiting Phase 1 Boehringer Ingelheim · Berlin · NCT07781631

• How well different and multiple doses of BI 3034701 are tolerated in adults with overweight or obesity

  This trial tests whether BI 3034701, given in varying doses, is safe and tolerated in adults who are overweight or obese and have at least one weight-related health issue.

  Recruiting Phase 1 Boehringer Ingelheim · Mannheim · NCT07754474

• See if survodutide helps people with type 2 diabetes control blood sugar

  This study tests survodutide versus placebo to see if it helps adults with type 2 diabetes manage their blood sugar.

  Recruiting at 15 sites Phase 3 Boehringer Ingelheim · Birmingham, Alabama and 100 other locations · NCT07754461

• Testing different dose levels of BI 3822971 in adults with advanced solid tumors

  A single-arm early-phase trial is testing how well BI 3822971 is tolerated in adults with advanced or metastatic solid cancers who have exhausted standard therapies.

  Recruiting at 5 sites Phase 1 Boehringer Ingelheim · Leuven and 10 other locations · NCT07744152

• Testing how well different doses of BI 3819026 can be tolerated alone and with ezabenlimab in advanced cancer

  This study tests whether varying doses of BI 3819026 can be tolerated by adults with advanced solid cancers, both by itself and in combination with ezabenlimab.

  Recruiting at 8 sites Phase 1 Boehringer Ingelheim · New Haven, Connecticut and 8 other locations · NCT07607678

• Testing Different Doses of BI 3812465 in Diabetic Macular Edema

  Researchers are testing whether varying doses of BI 3812465 can be tolerated in adults with center-involved diabetic macular edema.

  Recruiting at 26 sites Phase 1/2 Boehringer Ingelheim · Phoenix, Arizona and 28 other locations · NCT07553429

• Obrixtamig plus standard chemotherapy in advanced epNEC

  This trial tests whether adding obrixtamig to standard platinum-etoposide chemotherapy helps people with advanced extrapulmonary neuroendocrine cancer live longer than standard chemotherapy alone.

  Recruiting at 109 sites Phase 3 Boehringer Ingelheim · Scottsdale, Arizona and 169 other locations · NCT07544654

• Nerandomilast for fibrosing interstitial lung disease at risk of progression

  This trial tests whether nerandomilast can help adults with fibrosing interstitial lung disease who are at risk of their disease getting worse.

  Recruiting at 7 sites Phase 3 Boehringer Ingelheim · Birmingham, Alabama and 161 other locations · NCT07540988

• Nerandomilast for Systemic Sclerosis in Adults

  This study tests whether nerandomilast tablets can help adults with systemic sclerosis compared to a placebo.

  Recruiting at 67 sites Phase 3 Boehringer Ingelheim · Birmingham, Alabama and 247 other locations · NCT07497087

• Zongertinib with or without pembrolizumab and platinum chemotherapy in HER2-mutant NSCLC

  This trial tests whether zongertinib can be tolerated when given with platinum-based chemotherapy, with or without pembrolizumab, in adults with advanced HER2-mutant non-squamous NSCLC.

  Recruiting at 19 sites Phase 2 Boehringer Ingelheim · St Leonards, New South Wales and 19 other locations · NCT07486817

• Testing Different Doses of BI 3814916 for Safety in Healthy Adults

  This early-phase study tests how safe, tolerable, and how BI 3814916 behaves in the body across different doses in healthy men and women.

  Recruiting Phase 1 Boehringer Ingelheim · Edegem · NCT07486115

• How BI 3000202 behaves in the blood in people with and without liver problems

  This study tests how BI 3000202 moves through the body in healthy adults and adults with liver impairment.

  Recruiting Phase 1 Boehringer Ingelheim · San Antonio, Texas · NCT07486102

• Obrixtamig with atezolizumab, carboplatin, and etoposide for advanced small cell lung cancer

  This trial will test whether adding obrixtamig to atezolizumab plus carboplatin and etoposide helps people with extensive-stage small cell lung cancer live longer.

  Recruiting at 166 sites Phase 3 Boehringer Ingelheim · Mobile, Alabama and 241 other locations · NCT07472517

• Different doses of BI 3000202 for adults with lupus

  We are testing whether different doses of BI 3000202 can help adults with systemic lupus erythematosus (lupus).

  Recruiting at 87 sites Phase 2 Boehringer Ingelheim · Beverly Hills, California and 138 other locations · NCT07409181

• Nerandomilast in children with fibrosing ILD: tolerability and potential benefit

  This study tests whether nerandomilast is safe, tolerable, and helpful for children and teens with fibrosing interstitial lung disease.

  Recruiting at 26 sites Phase 3 Boehringer Ingelheim · Los Angeles, California and 46 other locations · NCT07366034

• Tenecteplase to help recovery after an ischemic stroke more than 4.5 hours after last seen well

  This trial will test whether a single IV dose of tenecteplase helps adults who had an ischemic stroke (including wake-up strokes) recover when treatment starts more than 4.5 hours after they were last seen well.

  Recruiting at 198 sites Phase 3 Boehringer Ingelheim · Buenos Aires and 257 other locations · NCT07361302

• BI 764198 for adults and adolescents with proteinuric kidney diseases

  This trial tests whether the oral medicine BI 764198 can help adults and adolescents who have certain proteinuric kidney diseases, including secondary FSGS, treatment‑resistant minimal change disease, Alport syndrome, or treatment‑resistant membranous nephropathy.

  Recruiting at 115 sites Phase 2 Boehringer Ingelheim · Huntsville, Alabama and 153 other locations · NCT07355296

• BI 3802876 for adults with compensated cirrhosis from MASH

  This study will test whether BI 3802876 given by IV infusion is tolerated and how different doses are handled in adults with compensated cirrhosis due to MASH.

  Recruiting at 19 sites Phase 2 Boehringer Ingelheim · Chandler, Arizona and 26 other locations · NCT07325526

• Different doses of BI 3820768 for adults with advanced germ cell, endometrial, or ovarian cancer

  This trial tests increasing doses of BI 3820768, an immune-stimulating injection, in adults with advanced, relapsed, or refractory germ cell, endometrial, or ovarian cancer to find a tolerable dose that may shrink tumors.

  Recruiting at 11 sites Phase 1 Boehringer Ingelheim · Los Angeles, California and 12 other locations · NCT07306559

• Different doses of BI 3810944 for adults with advanced solid tumors

  This trial tests different doses of the experimental drug BI 3810944 to see if adults with advanced solid tumours, including melanoma, who have not had success with standard treatments can tolerate it and might benefit.

  Recruiting at 5 sites Phase 1 Boehringer Ingelheim · Louisville, Kentucky and 6 other locations · NCT07224425

• BI 764198 for adults and adolescents with focal segmental glomerulosclerosis (FSGS).

  This study will test BI 764198 tablets taken once daily for up to two years in adults and adolescents with FSGS to see if it lowers urine protein and preserves kidney function.

  Recruiting at 253 sites Phase 3 Boehringer Ingelheim · Alabaster, Alabama and 314 other locations · NCT07220083

• Nerandomilast to slow lung changes in people with a family history of pulmonary fibrosis

  This trial tests whether taking nerandomilast can slow early lung scarring in people aged 40 and older who have a first-degree relative with pulmonary fibrosis and CT evidence of interstitial lung abnormalities.

  Recruiting at 52 sites Phase 3 Boehringer Ingelheim · Los Angeles, California and 54 other locations · NCT07201922

• Adjuvant zongertinib versus standard adjuvant care for completely resected Stage II–IIIB HER2 TKD–mutant NSCLC

  This trial tests whether taking oral zongertinib after surgery can help adults with completely resected Stage II–IIIB NSCLC whose tumors have activating HER2 TKD mutations live longer without the cancer coming back.

  Recruiting at 172 sites Phase 3 Boehringer Ingelheim · Fresno, California and 202 other locations · NCT07195695

• Vicadrostat with empagliflozin for people with type 2 diabetes, high blood pressure, and heart disease

  This trial will test whether adding vicadrostat to empagliflozin lowers cardiovascular risk in adults who have type 2 diabetes, high blood pressure, and existing cardiovascular disease but no history of heart failure.

  Recruiting at 1096 sites Phase 3 Boehringer Ingelheim · Anniston, Alabama and 1141 other locations · NCT07064473

• How the medicine BI 1291583 gets into the blood of people with and without liver problems.

  This will test how a single oral dose of BI 1291583 enters the bloodstream in adults with and without liver impairment.

  Recruiting Phase 1 Boehringer Ingelheim · Rialto, California and 3 other locations · NCT07023354

• BI 1815368 for centre-involved diabetic macular edema.

  This study will test whether the oral medicine BI 1815368 can improve vision in adults with centre-involved diabetic macular edema and determine the best dose.

  Recruiting at 79 sites Phase 2 Boehringer Ingelheim · Phoenix, Arizona and 96 other locations · NCT06962839

• Vicadrostat plus empagliflozin for people with heart failure and reduced left-sided pumping function

  This trial will test whether adding vicadrostat to empagliflozin helps adults with chronic heart failure who have a reduced left ventricular ejection fraction.

  Recruiting at 563 sites Phase 3 Boehringer Ingelheim · Beverly Hills, California and 593 other locations · NCT06935370

• BI 1291583 for people with bronchiectasis

  This study will test whether a once-daily pill called BI 1291583 can reduce flare-ups in people aged 12 and older who have bronchiectasis and produce sputum.

  Recruiting at 244 sites Phase 3 Boehringer Ingelheim · Birmingham, Alabama and 477 other locations · NCT06872892

• Testing how well different doses of BI 3776528 are tolerated in healthy men

  This study is testing how well different doses of a new medication are tolerated by healthy men aged 18 to 50.

  Recruiting Phase 1 Boehringer Ingelheim · Berlin · NCT06745297

• Testing BI 3032950 for Ulcerative Colitis

  This study is testing a new treatment called BI 3032950 to see if it can help adults with ulcerative colitis who haven't found relief from other treatments.

  Recruiting at 34 sites Phase 2 Boehringer Ingelheim · Scottsdale, Arizona and 40 other locations · NCT06636656

• Testing Survodutide for Liver Disease in Patients with Cirrhosis

  This study is testing if a new medication called survodutide can help improve liver function in adults with cirrhosis caused by liver fat buildup.

  Recruiting at 429 sites Phase 3 Boehringer Ingelheim · Peoria, Arizona and 446 other locations · NCT06632457

• Testing Survodutide for Liver Disease in Patients with NASH/MASH

  This study is testing a new medication called survodutide to see if it can help adults with liver disease related to metabolic dysfunction feel better and improve their liver health.

  Recruiting at 497 sites Phase 3 Boehringer Ingelheim · Birmingham, Alabama and 531 other locations · NCT06632444

• Testing Zongertinib for Advanced Cancers with HER2 Alterations

  This study is testing if a new drug called zongertinib can help adults with advanced cancers that have specific HER2 changes, especially after other treatments haven't worked.

  Recruiting at 81 sites Phase 2 Boehringer Ingelheim · Anchorage, Alaska and 92 other locations · NCT06581432

• Testing the safety and tolerability of BI 3804379 in healthy individuals

  This study is testing a new drug called BI 3804379 in healthy men and women to see if it's safe and how well their bodies handle it.

  Recruiting Phase 1 Boehringer Ingelheim · Edegem · NCT06575400

• Testing Vicadrostat with Empagliflozin for Heart Failure

  This study is testing if a new drug called vicadrostat, when taken with empagliflozin, can help adults with heart failure feel better compared to a placebo.

  Recruiting at 625 sites Phase 3 Boehringer Ingelheim · Mobile, Alabama and 670 other locations · NCT06424288

• Finding the right dose of zongertinib for HER2+ cancer treatment

  This study is testing the best dose of zongertinib to see if it can help adults with hard-to-treat HER2+ cancers shrink their tumors.

  Recruiting at 98 sites Phase 1/2 Boehringer Ingelheim · Cerritos, California and 103 other locations · NCT06324357

• Testing BI 764524 for treating diabetic retinopathy

  This study is testing a new eye treatment called BI 764524 to see if it can help adults with moderate to severe diabetic retinopathy improve their eye health.

  Recruiting at 2 sites Phase 2 Boehringer Ingelheim · Phoenix, Arizona and 89 other locations · NCT06321302

• Testing how a new medicine is absorbed by tumors in patients with advanced lung and neuroendocrine cancers

  This study is testing a new medicine to see how well it gets absorbed by tumors in adults with advanced lung or neuroendocrine cancers who haven't had success with other treatments.

  Recruiting Phase 1 Boehringer Ingelheim · Amsterdam · NCT05963867

• Testing a new treatment for brain tumors positive for DLL3

  This study is testing a new treatment for adults with advanced glioma that has the DLL3 marker to see if a special antibody can help their immune system fight the tumor better.

  Recruiting at 10 sites Phase 1 Boehringer Ingelheim · Orange, California and 11 other locations · NCT05916313

• Testing different doses of BI 764532 for small cell lung cancer and neuroendocrine cancers

  This study is testing different doses of a new cancer drug called BI 764532 to see if it can help adults with advanced small cell lung cancer and other neuroendocrine tumors that haven't responded to other treatments.

  Recruiting at 37 sites Phase 2 Boehringer Ingelheim · Mobile, Alabama and 58 other locations · NCT05882058

• CTD-related interstitial lung disease in Mexico: patterns, treatments, and outcomes

  This project will collect health data to see how interstitial lung disease linked to connective tissue diseases affects adults in Mexico and how other illnesses and treatments relate to progression, flare-ups, or death.

  Recruiting Boehringer Ingelheim · Mexico City · NCT05819385

• Testing a new cancer treatment with BI 1703880 and ezabenlimab

  This study is testing a new cancer treatment combining two medications to see if they can help adults with advanced tumors that haven’t responded to other treatments.

  Recruiting at 13 sites Phase 1 Boehringer Ingelheim · Los Angeles, California and 20 other locations · NCT05471856

• Testing zongertinib for advanced cancer with HER2 gene changes

  This study is testing a new drug called zongertinib to see if it can safely shrink tumors in adults with advanced cancer that have changes in the HER2 gene.

  Recruiting at 34 sites Phase 1 Boehringer Ingelheim · Birmingham, Alabama and 84 other locations · NCT04886804

Quick answers

How many clinical trials run by Boehringer Ingelheim are recruiting right now?

48, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 64 countries. The most sites are in Germany (32 trials), Japan (28 trials), United States (28 trials), Spain (27 trials), Belgium (27 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 19, Phase 3: 16, Phase 2: 9, Phase 1/2: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →